Security Snapshot

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - Common Stock (PACB) Institutional Ownership

CUSIP: 69404D108

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

227

Shares (Excl. Options)

188,156,013

Price

$1.32

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock
Symbol
PACB on Nasdaq
Shares outstanding
301,979,157
Price per share
$1.71
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
188,156,013
Total reported value
$248,502,592
% of total 13F portfolios
0%
Share change
-13,240,513
Value change
-$19,875,765
Number of holders
227
Price from insider filings
$1.71
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Key facts

  • PACB - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - Common Stock is tracked under CUSIP 69404D108.
  • 227 institutions reported positions in Q1 2026.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 213 to 227 between Q4 2025 and Q1 2026.
  • Reported value moved from $373,261,409 to $248,502,592.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 227 institutions filings for Q1 2026.

Open SEC Evidence

Security key

69404D108

Latest holder period

Q1 2026

13F holders

227

13D/G owners

5

CIK / CUSIP context first

Open Q1 2026 holders PACB full holder history PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SEC filings PACIFIC BIOSCIENCES OF CALIFORNIA, INC. company facts PACIFIC BIOSCIENCES OF CALIFORNIA, INC. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Significant Owners of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - Common Stock (PACB) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARK Investment Management LLC 12% +20% $69,684,106 +$11,856,034 37,264,228 +21% ARK Investment Management LLC 31 Dec 2025
BlackRock, Inc. 7.7% $25,381,202 22,865,948 BlackRock, Inc. 31 Mar 2025
EDMOND DE ROTHSCHILD ASSET MANAGEMENT (FRANCE) 4.5% $16,574,088 13,366,200 EDMOND DE ROTHSCHILD ASSET MANAGEMENT (FRANCE) 30 Jun 2025
MADRONE CAPITAL PARTNERS, LLC 2.8% -57% $10,849,394 -$15,086,243 8,476,089 -58% Gregory Boyd Penner 30 Sep 2025
MILLENNIUM MANAGEMENT LLC 0.7% -88% $2,446,489 -$15,805,969 2,204,044 -87% Millennium Management LLC 31 Mar 2025

As of 31 Mar 2026, 227 institutional investors reported holding 188,156,013 shares of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - Common Stock (PACB). This represents 62% of the company’s total 301,979,157 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - Common Stock (PACB) together control 54% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ARK Investment Management LLC 12% 36,273,288 -2.7% 0.37% $47,880,740
BlackRock, Inc. 8.4% 25,267,429 +8.2% 0% $33,353,006
SOFTBANK GROUP CORP. 6.8% 20,451,570 0% 0.24% $26,996,072
VANGUARD CAPITAL MANAGEMENT LLC 4.2% 12,777,449 0% 0% $16,866,233
Amova Asset Management Americas, Inc. 2.3% 7,037,987 -9.9% 0.13% $9,219,763
Sumitomo Mitsui Trust Group, Inc. 2.3% 7,037,987 -9.9% 0.01% $9,290,143
GEODE CAPITAL MANAGEMENT, LLC 2.3% 6,975,266 -1.5% 0% $9,209,906
STATE STREET CORP 2% 6,121,716 +3.5% 0% $8,080,665
MILLENNIUM MANAGEMENT LLC 1.6% 4,892,318 +13% 0% $6,457,860
D. E. Shaw & Co., Inc. 1.2% 3,637,547 -18% 0% $4,801,562
TWO SIGMA INVESTMENTS, LP 1.2% 3,509,613 +22% 0% $4,632,689
Nuveen, LLC 0.98% 2,950,929 +248% 0% $3,895,226
VANGUARD PORTFOLIO MANAGEMENT LLC 0.95% 2,868,393 0% 0% $3,786,279
RENAISSANCE TECHNOLOGIES LLC 0.82% 2,489,100 -35% 0.01% $3,285,612
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.8% 2,405,496 -2.4% 0% $3,175,255
NORTHERN TRUST CORP 0.71% 2,130,788 +4.1% 0% $2,812,640
VANGUARD FIDUCIARY TRUST CO 0.66% 1,986,483 0% 0% $2,622,158
MORGAN STANLEY 0.61% 1,840,460 -24% 0% $2,429,407
IQ EQ FUND MANAGEMENT (IRELAND) Ltd 0.59% 1,788,393 -5.6% 0.18% $2,360,679
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.57% 1,719,165 -34% 0% $2,269,298
BANK OF AMERICA CORP /DE/ 0.55% 1,666,706 -10% 0% $2,200,052
UBS Group AG 0.54% 1,640,099 -48% 0% $2,164,931
CITADEL ADVISORS LLC 0.52% 1,576,051 -50% 0% $2,080,387
Birchview Capital, LP 0.5% 1,500,000 +200% 1.1% $1,980,000
Invesco Ltd. 0.49% 1,468,148 +2.5% 0% $1,937,955

Institutional Holders of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - Common Stock (PACB) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 188,156,013 $248,502,592 -$19,875,765 $1.32 227
2025 Q4 200,682,911 $373,261,409 +$45,692,100 $1.87 213
2025 Q3 186,222,939 $237,845,533 -$15,544,161 $1.28 204
2025 Q2 198,429,992 $245,807,592 -$33,393,899 $1.24 201
2025 Q1 225,076,304 $265,438,365 -$42,568,126 $1.18 215
2024 Q4 259,359,536 $474,377,794 +$51,266,960 $1.83 224
2024 Q3 231,885,292 $394,223,882 -$15,146,412 $1.70 221
2024 Q2 242,322,324 $331,828,960 -$126,309,908 $1.37 221
2024 Q1 264,567,000 $991,987,863 -$194,324,005 $3.75 259
2023 Q4 280,691,608 $2,753,719,080 +$174,125,078 $9.81 264
2023 Q3 262,947,975 $2,195,398,479 +$60,147,076 $8.35 269
2023 Q2 253,730,383 $3,373,760,799 +$3,630,482 $13.30 261
2023 Q1 253,323,853 $2,930,177,608 +$337,446,210 $11.58 246
2022 Q4 224,875,103 $1,839,361,397 -$8,472,047 $8.18 224
2022 Q3 211,717,263 $1,230,031,332 -$113,902,446 $5.80 205
2022 Q2 225,422,707 $1,027,886,640 -$73,855,004 $4.42 210
2022 Q1 223,099,497 $2,031,587,303 +$56,829,128 $9.10 235
2021 Q4 205,231,110 $4,199,090,963 +$311,852,672 $20.46 242
2021 Q3 188,918,110 $4,827,498,627 +$390,443,256 $25.55 238
2021 Q2 172,487,642 $6,031,627,622 +$293,878,727 $34.97 253
2021 Q1 164,192,829 $5,468,916,669 -$280,136,379 $33.31 249
2020 Q4 140,067,694 $3,634,026,778 +$744,373,801 $25.94 149
2020 Q3 148,618,546 $1,467,458,670 +$444,724,505 $9.87 171
2020 Q2 108,792,315 $375,333,900 -$26,373,067 $3.45 145
2020 Q1 117,306,862 $358,961,836 -$19,512,348 $3.06 125
2019 Q4 115,201,561 $592,149,594 -$29,996,550 $5.14 133
2019 Q3 117,551,319 $606,570,421 -$16,643,818 $5.16 144
2019 Q2 120,417,909 $728,515,220 -$6,852,455 $6.05 145
2019 Q1 120,652,745 $872,331,967 +$96,392,269 $7.23 157
2018 Q4 107,153,063 $792,908,522 +$59,427,478 $7.40 150
2018 Q3 109,008,919 $589,718,249 +$86,063,166 $5.41 117
2018 Q2 93,208,345 $330,882,977 +$3,086,912 $3.55 97
2018 Q1 93,880,007 $192,464,420 +$32,466,834 $2.05 97
2017 Q4 77,673,837 $205,056,546 -$13,658,908 $2.64 103
2017 Q3 81,963,050 $430,249,897 +$22,193,371 $5.25 95
2017 Q2 78,967,536 $281,135,570 +$51,618,384 $3.56 103
2017 Q1 63,524,185 $328,395,282 +$48,916,595 $5.17 103
2016 Q4 63,181,144 $240,109,301 -$67,966,160 $3.80 111
2016 Q3 65,019,702 $582,560,386 +$26,681,843 $8.96 127
2016 Q2 61,281,293 $431,148,456 +$16,972,467 $7.04 140
2016 Q1 57,943,985 $490,940,000 +$38,917,343 $8.50 130
2015 Q4 52,286,294 $686,611,589 +$150,363,502 $13.13 119
2015 Q3 42,673,314 $156,171,185 -$4,365,999 $3.66 89
2015 Q2 42,651,245 $245,663,465 +$18,703,999 $5.76 100
2015 Q1 39,071,045 $228,161,111 +$4,609,300 $5.84 93
2014 Q4 43,639,561 $342,232,534 +$20,164,394 $7.84 99
2014 Q3 36,219,956 $177,825,215 -$6,558,040 $4.91 88
2014 Q2 37,290,143 $230,411,868 -$7,231,419 $6.18 86
2014 Q1 38,528,141 $205,820,143 +$5,919,971 $5.35 85
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .